Get the Stockscreener App
2.93
4.17%
0.05
After Hours:
2.74
-0.19
-6.48%
Purple Biotech Ltd Adr stock is traded at $2.93, with a volume of 47,020.
It is up +4.17% in the last 24 hours and down -33.92% over the past month.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.
See More
Previous Close:
$2.88
Open:
$2.7
24h Volume:
47,020
Relative Volume:
0.42
Market Cap:
$2.72M
Revenue:
-
Net Income/Loss:
$-26.67M
P/E Ratio:
-0.0859
EPS:
-34.108
Net Cash Flow:
$-5.54M
1W Performance:
-14.53%
1M Performance:
-33.92%
6M Performance:
-62.20%
1Y Performance:
-87.49%
1-Day Range:
$2.70
$3.08
1-Week Range:
$2.52
$3.24
52-Week Range:
$2.52
$28.30
Purple Biotech Ltd Adr Stock (PPBT) Company Profile
Compare PPBT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PPBT
Purple Biotech Ltd Adr
|
2.93 | 2.68M | 0 | -26.67M | -5.54M | -34.11 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Purple Biotech Ltd Adr Stock (PPBT) Latest News
Should I Buy PPBT (Purple Biotech Ltd.) | AI Analysis, Technical & News Insights - Kavout
PPBT Stock Price, Quote & Chart | PURPLE BIOTECH LTD-ADR (NASDAQ:PPBT) - ChartMill
PPBT Technical Analysis | Trend, Signals & Chart Patterns | PURPLE BIOTECH LTD-ADR (NASDAQ:PPBT) - ChartMill
PPBT Stock Earnings: Purple Biotech Beats EPS for Q2 2024 - Finviz
New LowStock ScreenerSnapshot - Finviz
Purple Biotech reports preclinical data for IM1240 cancer therapy - Investing.com
Gross margin % of Purple Biotech Ltd. Sponsored ADR – GETTEX:1YI0 - TradingView
Price to sales ratio of Purple Biotech Ltd. Sponsored ADR – GETTEX:1YI0 - TradingView
Purple Biotech Ltd (FRA:1YI0)Valuation Measures & Financial Statistics - GuruFocus
Purple Biotech Ltd (PPBT) Stock Price, Trades & News - GuruFocus
Purple Biotech Ltd (FRA:1YI0) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Purple Biotech Ltd (FRA:1YI0) Valuation - GuruFocus
Purple Biotech Ltd Stock Baskets - GuruFocus
Purple Biotech Ltd (STU:1YI0) Competitors 2026 - GuruFocus
Purple Biotech Ltd (STU:1YI0) Valuation - GuruFocus
Purple Biotech Ltd (STU:1YI0) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Purple Biotech Ltd (STU:1YI0) Stock Price, Trades & News - GuruFocus
Purple Biotech Ltd (STU:1YI0) Dividend - GuruFocus
Who's Buying or Selling Purple Biotech Ltd (STU:1YI0) Stock Today? - GuruFocus
Purple Biotech Ltd (STU:1YI0) Stock News, Headlines & Updates - GuruFocus
Purple Biotech Ltd Stock Operating Data - GuruFocus
Purple Biotech Ltd Stock Intrinsic Values - GuruFocus
Purple Biotech Ltd Stock Warning Signs - GuruFocus
Purple Biotech Ltd Stock Historical Valuations | STU:1YI0 - GuruFocus
Purple Biotech (NASDAQ: PPBT) outlines losses, pipeline and funding risks in 2025 20-F - Stock Titan
Form 6K PURPLE BIOTECH LTD. For: 17 March - Investing.com
Diluted earnings per share (diluted EPS) of Purple Biotech Ltd. Sponsored ADR – MUN:1YI0 - TradingView
Average basic shares outstanding of Purple Biotech Ltd. Sponsored ADR – MUN:1YI0 - TradingView
H.C. Wainwright cuts Purple Biotech stock price target to $30 By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Purple Biotech stock price target to $30 - Investing.com
Preferred dividends of Purple Biotech Ltd. Sponsored ADR – MUN:1YI0 - TradingView
Purple Biotech CEO Gil Efron to step down in August 2026 - Investing.com India
Purple Biotech Announces CEO Transition - ChartMill
Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial Results - ChartMill
Dilution adjustment of Purple Biotech Ltd. Sponsored ADR – MUN:1YI0 - TradingView
After tax other income/expense of Purple Biotech Ltd. Sponsored ADR – MUN:1YI0 - TradingView
Cash from financing activities of Purple Biotech Ltd. Sponsored ADR – FWB:1YI0 - TradingView
Cash from operating activities of Purple Biotech Ltd. Sponsored ADR – FWB:1YI0 - TradingView
Diluted shares outstanding of Purple Biotech Ltd. Sponsored ADR – FWB:1YI0 - TradingView
Revenue per share of Purple Biotech Ltd. Sponsored ADR – FWB:1YI0 - TradingView
Debt to equity ratio of Purple Biotech Ltd. Sponsored ADR – FWB:1YI0 - TradingView
Asset turnover of Purple Biotech Ltd. Sponsored ADR – FWB:1YI0 - TradingView
Net margin % of Purple Biotech Ltd. Sponsored ADR – FWB:1YI0 - TradingView
Price to book ratio of Purple Biotech Ltd. Sponsored ADR – FWB:1YI0 - TradingView
Long term debt to total equity ratio of Purple Biotech Ltd. Sponsored ADR – FWB:1YI0 - TradingView
Purple Biotech Ltd. Sponsored ADR Income Statement – FWB:1YI0 - TradingView
Purple Biotech Ltd. Sponsored ADR Statistics – FWB:1YI0 - TradingView
Purple Biotech Ltd. Sponsored ADR Earnings and Revenue – FWB:1YI0 - TradingView
Net debt of Purple Biotech Ltd. Sponsored ADR – FWB:1YI0 - TradingView
Purple Biotech Ltd. Sponsored ADR Balance Sheet – FWB:1YI0 - TradingView
Purple Biotech Ltd. Sponsored ADR Financial Statements – FWB:1YI0 - TradingView
Purple Biotech Ltd Adr Stock (PPBT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.49%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):